No Data
Pacific Securities: Q3 revenue and profit growth of the active pharmaceutical ingredient sector have accelerated significantly, bullish on the high growth trend in Q4 performance.
In Q1 2024, the gross margin of the sector was 36.38%, with a net margin of 12.78%. In Q2, the gross margin was 37.21%, with a net margin of 15.52%. In Q3, the gross margin was 38.27%, +1.88pct year-on-year, +1.06pct quarter-on-quarter, with a net margin of 14.07%, +3.98pct year-on-year, -1.45pct quarter-on-quarter, both gross margin and net margin reaching a new high compared to the same period in the past three years.
Jointown Pharmaceutical (300966.SZ): Currently, the company's business has not yet entered the AI field.
Gelonghui November 6th | Joint Pharmaceutical (300966.SZ) stated on the investor interaction platform that the current business of the company has not yet involved the AI field, and the company will carefully consider it in future development.
Kyodo Pharmaceutical: Third quarter report 2024
Jointown Pharma (300966.SZ): The net loss in the third quarter was 9.0436 million yuan.
On October 23, GeLongHui announced the third quarter report for 2024, with operating revenue of 0.132 billion yuan, a year-on-year increase of 12.24%; net income attributable to shareholders of listed companies -9.0436 million yuan; net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses -9.8436 million yuan; basic earnings per share -0.08 yuan.
Hubei Goto Biopharm Co.,Ltd.'s (SZSE:300966) Share Price Boosted 42% But Its Business Prospects Need A Lift Too
September 30 A-share lightning rod ︱ Joint Pharmaceutical: Shareholders Dan Venture Capital, Zhang Xin plan to collectively reduce their shareholding by no more than 3%; China Energy Construction: 18.206 billion shares of restricted shares will be unlocke
Shareholders Dan Venture Capital and Zhang Xin of Joint Pharmaceutical intend to jointly reduce their shareholding by no more than 3%; Shareholders holding more than 5% of Anlian Ruishi's shares and their concerted actions plan to reduce their shareholding by a total of no more than 2.93% of the company's shares; Shareholders Changcheng and Junlian Chengyu of Kangzhong Medical intend to jointly reduce their shareholding by no more than 2%; China Energy Construction indicates that 18.206 billion shares will be restricted from trading on September 30; *ST Yinjiang's stocks are subject to additional special treat risk warnings; There is still uncertainty in the equity transfer of Yonghui Superstores; ST Baili's stocks are subject to additional special treat risk warnings.
Hubei Goto Biopharm Co.,Ltd.'s (SZSE:300966) Share Price Boosted 31% But Its Business Prospects Need A Lift Too
